logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Success of the first trial of Opsumit (Actelion) in portopulmonary hypertension

Source: redaccionmedica.com

Actelion Pharmaceuticals has announced the results of the first randomized controlled trial in portopulmonary hypertension (HTPP). This study has shown that Opsumit (macitentan) significantly improves pulmonary vascular resistance (PVR) compared with placebo.

Presented as an oral communication at the recent meeting of the European Society of Pneumology (ERS) in Paris, the treatment of portopulmonary hypertension with macitentan also showed that its safety is consistent with that observed in previous clinical trials. PTSH is a subtype of pulmonary arterial hypertension (PAH), associated with portal hypertension (increased blood pressure in the portal vein) often due to liver cirrhosis.

“The findings are relevant because if patients with PTSH can receive treatment to successfully reduce pulmonary vascular pressure and resistance, more patients may be eligible for liver transplantation, since they will potentially have a better prognosis for this surgery,” he said. the principal investigator Olivier Sitbon. M.D., Ph.D., Professor of Respiratory Medicine at the University of South Paris.

“Consistent” security
The data that support the use of PAH therapies in patients with PPHT are extremely limited and come mainly from open studies of a single center 5-7. To date, none of the approved treatments for PAH had been shown to improve cardiopulmonary haemodynamics in patients with PPHT in a randomized controlled clinical trial.

“In the trial, patients were randomized to receive macitentan 10mg (n = 43) or placebo (n = 42) once a day. After 12 weeks of treatment, macitentan significantly improved the PVR (35% reduction versus placebo of the main variable), “explained Joan Albert Barberà, head of the Pneumology Service of the Hospital Clínic de Barcelona and researcher of the trial.

“The fact that the hepatic safety profile of macitentan in patients with HTPP is consistent with that observed in previous trials is particularly reassuring, since these patients with HTPP are typically excluded from clinical trials of PAH for safety reasons” comments the another Spanish researcher of the study, Pilar Escribano, coordinator of the Hypertension Unit of Hospital 12 de Octubre in Madrid.

In Distefar, we are pleased with these successes in the sector and represent an advance in patients with pulmonary problems

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.